

NSW/QLD EXCEPTIONAL DRUGS LIST – 1 January 2009 - replacing EDL Update of 1/5/2008

<p>Note 1: This Exceptional Drugs List has been developed for use in New South Wales & Queensland in accordance with the <i>Guidelines for the Funding of Exceptional Drugs in NSW & Queensland Private Hospitals</i> originally developed in December 1996 & revised by the EDL Committee in July 2004 & December 2008</p> <p>The List is maintained and regularly updated by the Exceptional Drugs List Committee.</p> <p style="color: red;">Amendments in this listing are noted in red.</p>	<p>Note 2: If an existing contract refers to the “Exceptional Drugs List”, the contract may not automatically adopt the revised List. Instead, the parties to the contract should negotiate on an individual basis whether the contract should apply this revised Exceptional Drugs List.</p> <p>Note 3: DRUG CODES: For EDL transmission purposes each code number should be preceded by DX00, making an 8-digit code.</p>	<p>Note 4: Anti-Infective Agents: Health funds will consider payment of benefits for anti-infective agents (<i>refer Guidelines – revised July 2004</i>) not specifically listed, providing the following criteria are met:</p> <ul style="list-style-type: none"> • The drug is required for other than the PBS indications and the ‘Victorian Drug Usage Advisory Committee Antibiotic Guidelines’ (which are recognised as national standards) are followed <u>OR</u> • In special circumstances, on the recommendation of a specialist microbiologist/pathologist.
---	---	---

Effective Date	EDL Drug Code	Generic Name	Trade Name	Indicative Class Index	Strength	Quantity	Form	Authority PBS	Restricted PBS	EDL Restrictions Special Criteria
1/1/01	5000	Aciclovir	Zovirax	Antiviral	250mg	5	Parenteral			
1/1/01	5010	Aciclovir	Zovirax	Antiviral	500mg	5	Parenteral			
1/1/01	5020	Aciclovir	Zyclir	Antiviral	250mg	5	Parenteral			
1/1/01	5021	Aciclovir	Acylo-v	Antiviral	250mg	5	Parenteral			
1/1/01	5030	Aciclovir	Acylo-v	Antiviral	200mg	25	PO	Moderate to severe genital herpes		
1/1/01	5040	Aciclovir	Zovirax	Antiviral	200mg	25	PO	Moderate to severe genital herpes		
1/1/01	5050	Aciclovir	Zovirax	Antiviral	200mg	90	PO	Moderate to severe genital herpes		
1/1/01	5060	Aciclovir	Zovirax	Antiviral	800mg	35	PO	Treatment of patients with herpes zoster in whom the duration of rash < 72 hours		
1/1/01	5070	Aciclovir	Zyclir	Antiviral	200mg	25	PO			
1/1/01	5080	Aciclovir	Zyclir	Antiviral	200mg	90	PO			
1/1/01	5090	Aciclovir	Zyclir	Antiviral	800mg	35	PO			
1/1/01	5100	Aciclovir	Acylo-v	Antiviral	200mg	90	PO	Moderate to severe genital herpes		
1/1/01	5110	Aciclovir	Acylo-v	Antiviral	800mg	35	PO	Treatment of patients with herpes zoster in whom the duration of rash < 72 hours		
1/1/01	5120	Amikacin Sulphate	Amikin	Antibiotic	500mg/2ml	1	Parenteral			
1/1/01	5130	Amikacin Sulphate	Amikacin injection	Antibiotic	500mg/2ml	5	Parenteral			

Effective Date	EDL Drug Code	Generic Name	Trade Name	Indicative Class Index	Strength	Quantity	Form	Authority PBS	Restricted PBS	EDL Restrictions / Special Criteria
1/7/02	5135	Amphotericin B Lipid Complex	Abelcet	Antifungal	100mg	10	Parenteral			Use in Patients who are either: <ul style="list-style-type: none"> • Already experiencing renal dysfunction, or • Infusion related toxicities, or • Have a proven life-threatening fungal infection in an immuno-compromised host
1/1/01	5136	Amphotericin B2	Ambisome	Antifungal	50mg	10	Parenteral			<ul style="list-style-type: none"> • Have a proven life-threatening fungal infection in an immuno-compromised host
1/1/01	5140	Apomorphine HCL	Apomine injection	CNS	10mg/1ml	5	SC			Section 100
1/1/01	5150	Azathioprine	Imuran	Immunology	50mg	1	Parenteral			
1/1/01	5160	Aztreonam	Azactam	Antibiotic	1g	5	Parenteral			
1/1/01	5190	Carmustine	BiCNU	Oncology	100mg	1	Parenteral			
1/1/01	5192	Cefepime	Maxipime	Antibiotic	500mg	1	Parenteral	TX of febrile neutropenia		
1/1/01	5193	Cefepime	Maxipime	Antibiotic	1g	1	Parenteral	TX of febrile neutropenia		
1/1/01	5194	Cefepime	Maxipime	Antibiotic	2g	1	Parenteral	TX of febrile neutropenia		
1/1/01	5201	Cefotaxime Sodium	Claforan Injection	Antibiotic	500mg	1	Parenteral		For infections where positive bacteriological 1/1/01evidence confirms that cefotaxime is an appropriate therapeutic agent; Septicaemia, suspected or proven.	
1/1/01	5240	Cefoxitin	Mefoxin	Antibiotic	1g	1	Parenteral			
1/1/01	5250	Cefoxitin	Mefoxin	Antibiotic	2g	1	Parenteral			

Effective Date	EDL Drug Code	Generic Name	Trade Name	Indicative Class Index	Strength	Quantity	Form	Authority PBS	Restricted PBS	EDL Restrictions / Special Criteria
1/1/01	5251	Cefpirome	Cefrom	Antibiotic	2g	14	Vial			Febrile neutropenia in bone marrow transplant patients
1/1/01	5252	Cefpirome	Cefrom	Antibiotic	1g	1	Parenteral			Febrile neutropenia in bone marrow transplant patients
1/1/01	5260	Ceftazidime Pentahydrate	Fortum Injection	Antibiotic	1g	1	Parenteral			
1/1/01	5270	Ceftazidime Pentahydrate	Fortum Injection	Antibiotic	2g	1	Parenteral			
1/1/01	5320	Ciprofloxacin Lactate	Ciproxin	Antibiotic	100mg	1	Parenteral			
1/1/01	5330	Ciprofloxacin Lactate	Ciproxin	Antibiotic	200mg	1	Parenteral			
1/1/01	5340	Clindamycin	Dalacin C	Antibiotic	300 mg/2ml	1	Parenteral			
1/1/01	5341	Clindamycin	Dalacin C	Antibiotic	600 mg/4ml	1	Parenteral			
1/1/01	5350	Clozapine	Clozaril	CNS	25mg	100	PO			Section 100
1/1/01	5360	Clozapine	Clozaril	CNS	100mg	100	PO			Section 100
1/1/01	5370	Cyclosporin	Sandimmun	Immunology	50 mg/ml	10	Parenteral			Section 100
1/1/01	5380	Cyclosporin	Sandimmun	Immunology	250mg/5ml	10	Parenteral			Section 100
1/1/01	5390	Cyclosporin	Neoral	Immunology	25mg	30	PO	Maintenance Therapy following S 100 approval. Refer Circular 1/10/03 for detail.		Section 100
1/1/01	5391	Cyclosporin	Neoral	Immunology	10mg	60	PO	Maintenance Therapy following S 100 approval. Refer Circular 1/10/03 for detail.		Section 100
1/1/01	5400	Cyclosporin	Neoral	Immunology	50mg	30	PO	Maintenance Therapy following S 100 approval. Refer Circular 1/10/03 for detail.		Section 100
1/1/01	5410	Cyclosporin	Neoral	Immunology	100mg	30	PO	Maintenance Therapy following S 100 approval. Refer Circular 1/10/03 for detail.		Section 100
1/1/01	5420	Cyclosporin	Neoral	Immunology	100mg/ml	50ml	PO	Maintenance Therapy following S 100 approval. Refer Circular 1/10/03 for detail.		Section 100
1/1/01	5430	Dacarbazine	Dacarbazine.	Oncology	200mg	1	Parenteral			
1/1/01	5470	Danaparoid NS	Orgaran	LMWH	750u/0.6ml	10	SC			For HITTS only
1/1/01	5480	Dantrolene	Dantrium	Musculo-Skeletal	20mg	12	Parenteral			

Effective Date	EDL Drug Code	Generic Name	Trade Name	Indicative Class Index	Strength	Quantity	Form	Authority PBS	Restricted PBS	EDL Restrictions / Special Criteria
		Sodium								
1/7/03	5481	Darbepoetin Alfa	Aranesp	Endocrine	10 micrograms /0.4mL	4	Parenteral			Section 100 Treatment of anaemia requiring transfusion, haemoglobin level <100g per L, associated with chronic renal failure,
1/7/03	5482	Darbepoetin Alfa	Aranesp	Endocrine	20 micrograms /0.5mL	4	Parenteral			Section 100 As above
1/7/03	5483	Darbepoetin Alfa	Aranesp	Endocrine	30 micrograms /0.3mL	4	Parenteral			Section 100 As above
1/7/03	5484	Darbepoetin Alfa	Aranesp	Endocrine	40 micrograms /0.4mL	4	Parenteral			Section 100 As above
1/7/03	5485	Darbepoetin Alfa	Aranesp	Endocrine	50 micrograms /0.5mL	4	Parenteral			Section 100 As above
1/7/03	5486	Darbepoetin Alfa	Aranesp	Endocrine	60 micrograms /0.3mL	4	Parenteral			Section 100 As above
1/7/03	5487	Darbepoetin Alfa	Aranesp	Endocrine	100 micrograms /0.5mL	4	Parenteral			Section 100 As above
1/7/03	5488	Darbepoetin Alfa	Aranesp	Endocrine	150 micrograms /0.3mL	4	Parenteral			Section 100 As above
1/9/04	5489	Darbepoetin Alfa	Aranesp	Endocrine	80 micrograms in 0.4 mL	4	Parenteral			Section 100 As above
1/1/01	5490	Desferrioxamine	Desferal	Haematology	500mg	10	Parenteral			Section 100
1/1/01	5500	Desmopressin Acetate	Minirin	Endocrine	4 mcg/ml	10	Parenteral			
1/1/01	5501	Desmopressin Acetate	Octostim	Endocrine	15 mcg/ml	5	Parenteral			
1/1/01	5520	Dinoprost	Prostin F2 Alpha	Obstetric	5mg/ml	1	Parenteral			
1/1/01	5521	Dinoprost	Prostin F2 Alpha	Obstetric	20mg/4ml	1	Parenteral			
1/1/01	5530	Dinoprostone	Prostin E2 Vaginal gel	Obstetric	2mg	1	PV			
1/1/01	5540	Dinoprostone	Prostin E2 Vaginal gel	Obstetric	1mg	1	PV			
1/1/03	5550	Disodium Pamidronate	Aredia & Pamisol	Oncology	15mg	4	Parenteral	Paget's Disease Hypercalcaemia of malignancy		Section 100
1/1/03	5560	Disodium Pamidronate	Aredia & Pamisol	Oncology	30mg	2	Parenteral	Paget's Disease Hypercalcaemia of malignancy		Section 100

Effective Date	EDL Drug Code	Generic Name	Trade Name	Indicative Class Index	Strength	Quantity	Form	Authority PBS	Restricted PBS	EDL Restrictions / Special Criteria
1/1/03	5561	Disodium Pamidronate	Pamisol	Oncology	60mg	1	Parenteral	Paget's Disease Hypercalcaemia of malignancy		Section 100
1/1/03	5570	Disodium Pamidronate	Aredia & Pamisol	Oncology	90mg	1	Parenteral	Paget's Disease Hypercalcaemia of malignancy		Section 100 Multiple Myeloma Bone Metastases from Breast Cancer
1/1/01	5577	Dolasetron Mesylate	Anzemet	Antiemetic	12.5mg	1	Parenteral			Day only, gynaecological and paediatric surgery; patients using PCA with morphine
1/1/01	5630	Erythropoietin	Eprex	Endocrine	2000u/0.5 ml	6	Parenteral			Section 100 Payable for Chronic Renal Failure.
1/10/01	5631	Erythropoietin	Eprex	Endocrine	1000u/0.5ml	6	Parenteral			Section 100 As Above
1/10/01	5632	Erythropoietin	Eprex	Endocrine	3000u/0.5ml	6	Parenteral			Section 100 As Above
1/10/01	5634	Erythropoietin	Eprex	Endocrine	5000u/0.5ml	6	Parenteral			Section 100 As Above
1/10/01	5635	Erythropoietin	Eprex	Endocrine	6000u/0.6ml	6	Parenteral			Section 100 As Above
1/10/01	5637	Erythropoietin	Eprex	Endocrine	8000u/0.8ml	6	Parenteral			Section 100 As Above
1/9/04	5639	Erythropoietin	Eprex	Endocrine	20000u/0.5ml	6	Parenteral			Section 100 As Above
1/1/01	5640	Erythropoietin	Eprex	Endocrine	4000u/0.4ml	6	Parenteral			Section 100 As Above
1/1/01	5650	Erythropoietin	Eprex	Endocrine	10000u/1 ml	6	Parenteral			Section 100 As Above
1/10/01	5651	Erythropoietin	Eprex	Endocrine	40000u/1 ml	6	Parenteral			Section 100 As Above
1/1/01	5660	Ethambutol	Myambutol	Antibiotic	400mg	100	PO			
1/1/01	5661	Ethambutol	Myambutol	Antibiotic	100mg	100	PO			
1/1/01	5670	Filgrastim	Neupogen	Immunology	300 microgram	10	Parenteral			Section 100
1/1/01	5680	Filgrastim	Neupogen	Immunology	480 microgram	10	Parenteral			Section 100
1/1/01	5690	Finasteride	Proscar	Oncology	5mg	30	PO			
1/8/08	5720	Fludarabine	Fludara	Oncology	50mg	5	Parenteral			Section 100 B-cell Chronic lymphocytic leukaemia in combination with cyclophosphamide where the patient has advanced disease (Binet)

Effective Date	EDL Drug Code	Generic Name	Trade Name	Indicative Class Index	Strength	Quantity	Form	Authority PBS	Restricted PBS	EDL Restrictions / Special Criteria
										Stage B or C) or evidence of progressive Stage A disease.
1/1/01	5730	Ganciclovir Sodium	Cymevene	Antiviral	500mg	1	Parenteral			Section 100
1/1/01	5740	Gemeprost	Cervagem Pessaries	Obstetric	1mg	1	PV			
1/1/01	5750	Idarubicin	Zavedos	Oncology	5mg	1	Parenteral		Acute Myelogenous Leukaemia	
1/1/01	5760	Idarubicin	Zavedos	Oncology	10mg	1	Parenteral		Acute Myelogenous Leukaemia	
1/1/01	5770	Idarubicin	Zavedos	Oncology	5mg	1	PO		Acute Myelogenous Leukaemia	
1/1/01	5780	Idarubicin	Zavedos	Oncology	10mg	1	PO		Acute Myelogenous Leukaemia	
1/1/01	5790	Idarubicin	Zavedos	Oncology	25mg	1	PO		Acute Myelogenous Leukaemia	
1/1/01	5800	Imipenem	Primaxin	Antibiotic	250mg	1	Parenteral			
1/1/01	5810	Imipenem	Primaxin	Antibiotic	500mg	1	Parenteral			
1/7/02	5812	Interferon Alfa – 2b	Intron A	Immunology	3 mil units in 0.5ml	5	Parenteral			
1/7/02	5813	Interferon Alfa – 2b	Intron A	Immunology	5mil units in 0.5ml	5	Parenteral			
1/7/02	5814	Interferon Alfa – 2b	Intron A	Immunology	10 mil units in 1ml	5	Parenteral			Section 100
1/7/02	5815	Interferon Alfa – 2b	Intron A	Immunology	18 mil units in 1.2 ml	1	Parenteral	<ul style="list-style-type: none"> Hairy Cell Leukaemia Maintenance & treatment of Multiple Myeloma Low grade non-Hodgkins lymphoma 		Section 100
1/7/02	5816	Interferon Alfa – 2b	Intron A	Immunology	18 mil units in 3ml	5	Parenteral			Section 100
1/7/02	5817	Interferon Alfa – 2b	Intron A	Immunology	25 mil units in 2.5ml	5	Parenteral			Section 100
1/7/02	5818	Interferon Alfa – 2b	Intron A Redipen	Immunology	30 mil units in 1.2ml	1	Parenteral	<ul style="list-style-type: none"> Maintenance & treatment of Multiple Myeloma Low grade non-Hodgkins lymphoma 		Section 100

Effective Date	EDL Drug Code	Generic Name	Trade Name	Indicative Class Index	Strength	Quantity	Form	Authority PBS	Restricted PBS	EDL Restrictions / Special Criteria
1/7/02	5819	Interferon Alfa - 2b	Intron A Redipen	Immunology	60 mil units in 1.2ml	1	Parenteral			Section 100
1/4/02	5820	Interferon Alfa - 2a	Roferon – A (PFS)	Immunology	3 mil units	11	Parenteral	Hairy Cell Leukaemia Myeloproliferative disease with excessive thrombocytosis Low grade non-Hodgkin's lymphoma		Section 100
1/4/02	5821	Interferon Alfa - 2a	Roferon – A (PFS)	Immunology	3 mil units	15	Parenteral	Hairy Cell Leukaemia Myeloproliferative disease with excessive thrombocytosis Low grade non-Hodgkin's lymphoma		
1/1/01	5830	Interferon Alfa - 2a	Roferon – A (PFS)	Immunology	4.5 mil units	1	Parenteral			Section 100
1/4/02	5831	Interferon Alfa - 2a	Roferon – A (PFS)	Immunology	4.5 mil units	5	Parenteral	Myeloproliferative disease with excessive thrombocytosis Low grade non-Hodgkin's lymphoma		
1/4/02	5832	Interferon Alfa - 2a	Roferon – A (PFS)	Immunology	6 mil units	5	Parenteral	Myeloproliferative disease with excessive thrombocytosis Low grade non-Hodgkin's lymphoma		
1/1/01	5840	Interferon Alfa - 2a	Roferon – A (PFS)	Immunology	6 mil units	1	Parenteral			Section 100
1/1/01	5841	Interferon Alfa - 2a	Roferon – A (PFS)	Immunology	9 mil units	1	Parenteral			Section 100
1/4/02	5842	Interferon Alfa - 2a	Roferon – A (PFS)	Immunology	9 mil units	5	Parenteral	Myeloproliferative disease with excessive thrombocytosis Low grade non-Hodgkin's lymphoma		
1/7/03	5844	Interferon Alpha 2b	PEG-Intron	Immunology	50 micrograms	4	Parenteral	Chronic Hep C in patients 18+ years who have compensated liver disease & no prior interferon therapy.		Section 100
1/7/03	5845	Interferon Alpha 2b	PEG – Intron	Immunology	80 micrograms	4	Parenteral	Chronic Hep C in patients 18+ years who have compensated liver disease & no prior interferon therapy.		Section 100
1/7/03	5846	Interferon Alpha 2b	PEG – Intron	Immunology	100 micrograms	4	Parenteral	Chronic Hep C in patients 18+ years who have compensated liver disease		Section 100

Effective Date	EDL Drug Code	Generic Name	Trade Name	Indicative Class Index	Strength	Quantity	Form	Authority PBS	Restricted PBS	EDL Restrictions / Special Criteria
								& no prior interferon therapy.		
1/7/03	5847	Interferon Alpha 2b	PEG – Intron	Immunology	120 micrograms	4	Parenteral	Chronic Hep C in patients 18+ years who have compensated liver disease & no prior interferon therapy.		Section 100
1/7/03	5848	Interferon Alpha 2b	PEG – Intron	Immunology	150 micrograms	4	Parenteral	Chronic Hep C in patients 18+ years who have compensated liver disease & no prior interferon therapy.		Section 100
1/1/01	5850	Lenograstim	Granocyte	Immunology	33.6*10 ⁶ iu	1	Parenteral			Section 100
1/1/01	5851	Lenograstim	Granocyte	Immunology	13.4*10 ⁶ iu	1	Parenteral			Section 100
1/1/01	5860	Lomustine	CEENU	Oncology	10mg	20	PO			
1/1/01	5870	Lomustine	CEENU	Oncology	40mg	20	PO			
1/1/01	5880	Lomustine	CEENU	Oncology	100mg	20	PO			
1/1/01	5901	Melphalan	Alkeran	Oncology	50mg iv	1	Parenteral			
1/1/01	5906	Meropenem	Merrem IV	Antibiotic	500mg	1	Parenteral			
1/1/01	5907	Meropenem	Merrem IV	Antibiotic	1g	1	Parenteral			
1/1/01	5911	Mesna	Uromitexan	Oncology	400mg	50	PO			
1/1/01	5921	Mesna	Uromitexan	Oncology	600mg	50	PO			
1/1/01	5926	Methylprednisolone	Solu-Medrol	Endocrine	500mg/8ml	1	Parenteral			
1/1/01	5950	Mitomycin	Mitomycin C	Oncology	2mg	10	Parenteral			
1/1/01	5960	Mitomycin	Mitomycin C	Oncology	10mg	5	Parenteral			
1/1/01	5970	Mitomycin	Mitomycin C	Oncology	20mg	5	Parenteral			
						1	Parenteral			
1/1/01	6050	Nimodipine	Nimotop	Cardiovascular	30mg	100	PO			Cerebral vascular incidents: <ul style="list-style-type: none"> Prophylaxis against delayed ischaemic deficits or vasospasm following subarachnoid haemorrhage <ul style="list-style-type: none"> Treatment of cerebral arterial vasospasm
1/1/01	6060	Nimodipine	Nimotop	Cardiovascular	.02%	5	Parenteral			Cerebral vascular incidents: <ul style="list-style-type: none"> Prophylaxis against delayed

Effective Date	EDL Drug Code	Generic Name	Trade Name	Indicative Class Index	Strength	Quantity	Form	Authority PBS	Restricted PBS	EDL Restrictions / Special Criteria
										ischaemic deficits or vaso-spasm following subarachnoid haemorrhage <ul style="list-style-type: none"> Treatment of cerebral arterial vasospasm
1/1/02	6061	Octreotide	Sandostatin	Endocrine	0.05mg/ml	5	SC			Section 100
1/1/02	6062	Octreotide	Sandostatin	Endocrine	0.1mg/ml	5	SC			Section 100
1/1/02	6063	Octreotide	Sandostatin	Endocrine	0.5mg/ml	5	SC			Section 100
1/1/02	6064	Oestradiol Implants	Oestradiol Implants	Endocrine	20mcg	1	Implant			
1/1/02	6065	Oestradiol Implants	Oestradiol Implants	Endocrine	50mcg	1	Implant			
1/1/02	6066	Oestradiol Implants	Oestradiol Implants	Endocrine	100mcg	1	Implant			
1/1/01	6070	Ondansetron		Antiemetic	4mg/2ml	1	Parenteral	Management of nausea and vomiting associated with radiotherapy	Management of nausea and vomiting associated with cytotoxic chemotherapy	Day only surgery; gynaecological surgery; paediatric surgery; patients using PCA with morphine
1/1/01	6080	Ondansetron		Antiemetic	8mg/4ml	1	Parenteral	Management of nausea and vomiting associated with radiotherapy	Management of nausea and vomiting associated with cytotoxic chemotherapy	Day only surgery; gynaecological surgery; paediatric surgery; patients using PCA with morphine
1/10/01	6101	Parenteral Nutrition Solutions	2 in 1 Formula Amino Acid & Glucose	Nutrition	Up to 1 Litre Bags	See Special Criteria	Parenteral			1, 2 or 3 Bags Per Day (according to criteria below)
1/10/01	6103	Parenteral Nutrition Solutions	3 in 1 Formula Amino Acid / Glucose / Lipid Emulsion	Nutrition	Up to 3 Litres		Parenteral			Patients unable to be fed orally or enterally in hospitals with critical care facilities and access to pharmacy services with experience in TPN therapy
1/10/01	6105	Parenteral Nutrition Solutions	3 in 1 Formula Amino Acid /	Nutrition	Up to 2.5 Litres		Parenteral			As above

Effective Date	EDL Drug Code	Generic Name	Trade Name	Indicative Class Index	Strength	Quantity	Form	Authority PBS	Restricted PBS	EDL Restrictions / Special Criteria
			Glucose / Lipid Emulsion / Glutamine enriched							
1/10/01	6107	Additives Supplementar y Fee to codes 6101, 6103, 6105		Nutrition	Up to 3 Litre Bags	See Special Criteria	Parenteral			As above Additives are Vitamins, Trace Elements & Electrolytes
1/9/05	6180	Parenteral Nutrition Solutions	Clinoleic 20%	Nutrition	250 mls	1	Parenteral			As Above
1/1/01	6190	Parenteral Nutrition Solutions	Intralipid /Ivelip 10%	Nutrition	500 mls	1	Parenteral			As above
1/9/05	6200	Parenteral Nutrition Solutions	Intralipid / Ivelip 20% Clinoleic 20%	Nutrition	500 mls	1	Parenteral			As above
1/1/01	6210	Pentamidine	Pentamidine	Antibiotic	300mg	1	Parenteral			
1/1/01	6220	Piperacillin Sodium	Pipril	Antibiotic	1g	10	Parenteral			Discontinued but stocks still available
1/1/01	6230	Piperacillin Sodium	Pipril	Antibiotic	2g	10	Parenteral			
1/4/02	6240	Tazobactam/ Piperacillin	Tazocin	Antibiotic	2.25g	1	Parenteral			
1/4/02	6250	Tazobactam/ Piperacillin	Tazocin	Antibiotic	4.5g	1	Parenteral			
1/1/01	6260	Pyrazinamide	Zinamide	Antibiotic	500mg	100	PO			
1/1/01	6270	Rifampicin	Rimycin	Antibiotic	150mg	100	PO	Leprosy	Prophylactic treatment of contacts of patients with Haemophilus influenzae Type b; Prophylaxis of meningococcal disease in close contacts and carriers	

Effective Date	EDL Drug Code	Generic Name	Trade Name	Indicative Class Index	Strength	Quantity	Form	Authority PBS	Restricted PBS	EDL Restrictions / Special Criteria
1/1/01	6280	Rifampicin	Rimycin	Antibiotic	300mg	100	PO	Leprosy	Prophylactic treatment of contacts of patients with Haemophilus influenzae Type b; Prophylaxis of meningococcal disease in close contacts and carriers	
1/1/01	6285	Sodium Fusidate	Fucidin	Antibiotic	500mg	1	Parenteral			
1/1/01	6290	Sumatriptan Succinate	Imigran	CNS	6mg/0.5ml	2	Parenteral			
1/1/01	6291	Survanta	Beractant		25mg/8ml	1	Intra tracheal			Tx for ventilated babies with RDS at approved facilities
1/1/01	6320	Testosterone	Testosterone Implant	Endocrine	100mg	1	Implant			
1/1/01	6321	Testosterone	Testosterone Implant	Endocrine	200mg	1	Implant			
1/1/01	6380	Tropisetron	Navoban	Antiemetic	2mg/2ml	1	Parenteral			Day only surgery; gynaecological surgery; paediatric surgery; patients using PCA with morphine
1/1/01	6390	Tropisetron	Navoban	Antiemetic	5mg/5ml	1	Parenteral		Management of nausea and vomiting associated with cytotoxic chemotherapy	Day only surgery; gynaecological surgery; paediatric surgery; patients using PCA with morphine
1/1/01	6400	Vancomycin HCL	Vancocin	Antibiotic	500mg	1	Parenteral		Prophylaxis of endocarditis in patients hypersensitive to penicillin; Endophthalmitis; Use initiated in a hospital.	

Effective Date	EDL Drug Code	Generic Name	Trade Name	Indicative Class Index	Strength	Quantity	Form	Authority PBS	Restricted PBS	EDL Restrictions / Special Criteria
1/1/01	6401	Vancomycin HCL	Vancocin	Antibiotic	1g	1	Parenteral		Prophylaxis of endocarditis in patients hypersensitive to penicillin; Endophthalmitis; Use initiated in a hospital.	
1/1/05	6402	Voriconazole	VFend	Antifungal	200mg	50	Oral			<ul style="list-style-type: none"> Invasive Aspergillosis Serious fungal infections caused by <i>Scedosporium</i> spp or <i>Fusarium</i> spp Serious <i>Candida</i> infections where treatment with amphotericin or fluconazole has failed or is not tolerated.
1/1/05	6403	Voriconazole	VFend	Antifungal	200mg	1	Parenteral			<ul style="list-style-type: none"> Invasive Aspergillosis Serious fungal infections caused by <i>Scedosporium</i> spp or <i>Fusarium</i> spp Serious <i>Candida</i> infections where treatment with amphotericin or fluconazole has failed or is not tolerated.
1/1/02	6410	Vindesine	Eldisine	Oncology	5mg	1	Parenteral			

EDL UPDATE – 1 January 2009 Replacing EDL Update of 1/5/2008

**NSW/QLD EXCEPTIONAL DRUG LIST
DELETED ITEMS**

Code	Generic Name	Trade Name	Strength	Form	Reason for Deletion	Date of Effect
5980	Mustine HCL	Mustine HCL	10mg	Parenteral	No longer available	1 st October 2002
5440	Dalteparin Sodium	Fragmin	2500	Parenteral	Now on PBS	1 st October 2002
5441	Dalteparin Sodium	Fragmin	5000	Parenteral	Now on PBS	1 st July 2002
5450	Dalteparin Sodium	Fragmin	5000	Parenteral	Now on PBS	1 st July 2002
5451	Dalteparin Sodium	Fragmin	7,500	Parenteral	Now on PBS	1 st July 2002
5460	Dalteparin Sodium	Fragmin	10000	Parenteral	Now on PBS	1 st July 2002
5461	Dalteparin Sodium	Fragmin	7,500u/0.75ml	Parenteral	Now on PBS	1 st July 2002
5462	Dalteparin Sodium	Fragmin	10000	Parenteral	Now on PBS	1 st July 2002
5580	Enoxaparin Sodium	Clexane Injection	20mg/0.2ml	Parenteral	Now on PBS	1 st April 2002
5589	Enoxaparin Sodium	Clexane Injection	40mg/0.4ml	Parenteral	Now on PBS	1 st April 2002
5590	Enoxaparin Sodium	Clexane Injection	40mg/0.4ml	Parenteral	Now on PBS	1 st April 2002
5591	Enoxaparin Sodium	Clexane Injection	40mg/0.4ml	Parenteral	Now on PBS	1 st April 2002
5592	Enoxaparin Sodium	Clexane Injection	60mg/0.6ml	Parenteral	Now on PBS	1 st April 2002
5600	Enoxaparin Sodium	Clexane Injection	60mg/0.6ml	Parenteral	Now on PBS	1 st April 2002
5610	Enoxaparin Sodium	Clexane Injection	80mg/0.8ml	Parenteral	Now on PBS	1 st April 2002
5611	Enoxaparin Sodium	Clexane Injection	100mg/ml	Parenteral	Now on PBS	1 st April 2002
5620	Enoxaparin Sodium	Clexane Injection	100mg/ml (pack 15)	Parenteral	Now on PBS	1 st April 2002
5636	Epoetin Alpha	Eporex	7000u/0.5ml	Parenteral	Size no longer available	1 st September 2004
5638	Epoetin Alpha	Eporex	9000u/0.5ml	Parenteral	Size no longer available	1 st September 2004
5180	Calcium Folate	Leucovorin Calcium	50mg/5ml	Parenteral	Now on PBS	1 st April 2005
5181	Calcium Folate	Leucovorin Calcium	100mg/10ml	Parenteral	Now on PBS	1 st April 2005
5927	Methylprednisolone	Solu-Medrol	1000mg/16 ml	Parenteral	Now on PBS	1 st August 2005
6220	Piperacillin Sodium	Pipril	1g & 2 g	Parenteral	Product discontinued	1 September 2006 – unless shelf stock still available

EDL UPDATE – 1 January 2009 Replacing EDL Update of 1/5/2008

Code	Generic Name	Trade Name	Strength	Form	Reason for Deletion	Date of Effect
5170	Calcium Folate	Leucovorin Calcium Inj USP	50 mg/5ml	Parenteral	Now on PBS	1 January 2007
5171	Calcium Folate	Leucovorin Calcium Inj USP	15 mg/2ml	Parenteral	Now on PBS	1 January 2007
5700	Fluconazole	Diflucan	2mg/ml 50ml	Parental	Now on PBS	1 September 2007
5710	Fluconazole	Diflucan	2mg/ml 100ml	Parental	Now on PBS	1 September 2007

Note: 5700/5710 – Fluconazole. At its September 2007 meeting, the EDL Committee recommended that in circumstances where it might be prescribed outside PBS indications, IPU arrangements should apply.

DRUGS RECOMMENDED BY EDL COMMITTEE FOR FUNDING CONSIDERATION UNDER IPU ARRANGEMENTS

DRUG DESCRIPTION	Special Conditions/Comments	DATE OF RECOMMENDATION	DATE RECOMMENDATION REVIEWED
Amphotericin Lipid Complex		May 2000	29 May 2007
Soluvit N & Vitalip N		August 2000	29 May 2007
Urokinase (any alternative products to Ukiden)		November 2001	29 May 2007
Fotomustine 20 mg parenteral in place of Mustine HCL		August 2002	29 May 2007
Zometa (Zoledronic Acid)	<i>S100: Multiple myeloma; Bone metastases from Breast Cancer; Bone metastases from hormone resistant prostate cancer with demonstration of biochemical progress of disease despite maximal therapy with hormone treatments: Treatment of hypercalcaemia of malignancy refractory to anti-neoplastic therapy.</i>	August 2002	29 May 2007
Acalsta (Zoledronic Acid)	<i>Authority Required: Treatment as the sole PBS-subsidised anti-resorptive agent for established osteoporosis in men and women with fracture due to minimal trauma. In all cases the fracture must have been demonstrated radiologically and the year of plain x-ray or CT-scan or MR scan must be documented in the patient's medical records when treatment is initiated. Only one treatment each year for 3 consecutive years per patient will be PBS subsidized.</i>	1 December 2008	1 December 2008
Pegfilgrastim		May 2003	29 May 2007

EDL UPDATE – 1 January 2009 Replacing EDL Update of 1/5/2008

**DRUGS RECOMMENDED FOR REMOVAL BY EDL COMMITTEE FOR FUNDING CONSIDERATION
UNDER IPU ARRANGEMENTS**

DRUG DESCRIPTION	REASON	DATE DELETED
Herceptin	Accessible under PBS from 1 October 2006	1 October 2006
Arixtra (Fondaparinux Sodium) – antithrombotic therapy	Accessible under PBS	29 May 2007
Rheomacrodex IV INF 500 ml (Dextran 40 with glucose)		29 May 2007
Rheomacrodex IV INF 500 ml (Dextran 40 with sodium chloride)		29 May 2007
Macrodex IV INF 500 ml (Dextran 70 with sodium chloride)		29 May 2007
Infliximab (Crohn's Disease)	Accessible under PBS from 1 October 2007	1 October 2007
Taxotere for prostate cancer patients	Accessible under PBS from 1 November 2007	1 November 2007

Note: Taxotere: At its meeting in September 2007, the EDL Committee noted that Taxotere is listed on the PBS for the treatment of breast cancer (including HER2 breast cancer), Ovarian cancer, small cell lung cancer and from 1 November 2007 – Prostate Cancer. It was noted that currently there is no evidence regarding its use in the treatment of cancers not noted, however it was agreed that if in the future, the Committee received an application for use of this drug in the treatment of other cancers (where TGA approved), it would be recommended for listing under IPU arrangements.